EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Idelalisib 8-oxidation as an enzyme-selective catalytic marker of human aldehyde oxidase in HepG2 cells: Application to the investigation of enzyme inactivation

Nicholas Kai Ming Ng, Sian Wen Chan, Andres Kai Zhi Lim, Min Hao Eng, Vijaya Saradhi Mettu, Aik Jiang Lau

Drug Metabolism and Disposition · 2026-10 · 54 (10) · 100397

DOI: 10.1016/j.dmd.2026.100397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-10. Verfasst von Nicholas Kai Ming Ng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Aldehyde Oxidase, Purines. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Medical Research Council, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldehyde oxidase 1 (AOX1) is a cytosolic drug-metabolizing enzyme. Idelalisib is a phosphoinositide-3-kinase-delta inhibitor that undergoes extensive biotransformation, mainly via 8-oxidation, which is catalyzed predominantly by human AOX1 and, to a lesser extent, cytochromes P450. In the present study, the primary objective was to test the hypothesis that idelalisib 8-oxidation is an enzyme-selective catalytic marker of AOX1 in HepG2 human hepatocellular carcinoma cells that express AOX1 but has little or no CYP3A functionality, and this approach is effective in identifying AOX1 inactivators. Enzyme kinetic analysis indicated comparable values of kcat, Km, and ratio of kcat/Km (catalytic efficiency) for idelalisib 8-oxidation catalyzed by HepG2 cells and human liver cytosol, whereas Vmax was greater for liver cytosol-catalyzed idelalisib 8-oxidation. Human recombinant AOX1, CYP3A4, and CYP3A5 were major catalysts of idelalisib 8-oxidation. However, experiments with a panel of enzyme-selective chemical inhibitors indicated that AOX1, but not cytochrome P450 or xanthine oxidase, was responsible for idelalisib 8-oxidation in HepG2 cells and human liver cytosol. The HepG2 cell-catalyzed idelalisib 8-oxidation assay correctly identified time-dependent AOX1 inactivators (erlotinib, O-desmethylerlotinib, O-didesmethylerlotinib, and hydralazine) and noninactivators (gefitinib, O-desmethylgefitinib, O-desmorpholinopropylgefitinib, and raloxifene). The data from the experiment to address our secondary objective indicated that erlotinib dosing increased the accumulation of idelalisib and 8-oxo-idelalisib in mouse plasma, liver, and kidney. In conclusion, (1) idelalisib 8-oxidation is an AOX1-selective catalytic marker in HepG2 cells that can be used to study AOX1 catalytic function; and (2) the in vivo mouse pharmacokinetic approach is not effective in identifying erlotinib as an inhibitor of idelalisib 8-oxidation. SIGNIFICANCE STATEMENT: Idelalisib 8-oxidation as an aldehyde oxidase 1 (AOX1)-selective catalytic marker in HepG2 cells provides a convenient experimental platform to study AOX1 catalytic function, eg, time-dependent inactivation. The experimental tools for AOX1 research can now include a dual AOX1-CYP3A substrate to be used as an AOX1-selective catalytic marker in a cellular system (eg, HepG2 cells) that expresses AOX1 but lacks CYP3A functionality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aldehyde OxidasePurinesHumansHep G2 CellsOxidation-ReductionCytosolEnzyme InhibitorsAnimalsKineticsLiver

Stichwörter der Autor:innen

Aldehyde oxidaseCatalytic markerEnzyme inactivationErlotinibHepG2 cellsIdelalisib 8-oxidation

Substanzen

Aldehyde OxidaseAOX1 protein, humanPurinesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.
  • Biological Resource Centre, Agency for Science, Technology and Research, Singapore, Singapore.
  • College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, Canada; Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Canada. Electronic address: aikjiang.lau@dal.ca.

Förderung

  • National Medical Research Council
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Ng, N. K. M., Chan, S. W., Lim, A. K. Z., Eng, M. H., Mettu, V. S., & Lau, A. J. (2026). Idelalisib 8-oxidation as an enzyme-selective catalytic marker of human aldehyde oxidase in HepG2 cells: Application to the investigation of enzyme inactivation. Drug Metabolism and Disposition, 54(10), 100397. https://doi.org/10.1016/j.dmd.2026.100397

Vancouver

Ng NKM, Chan SW, Lim AKZ, Eng MH, Mettu VS, Lau AJ. Idelalisib 8-oxidation as an enzyme-selective catalytic marker of human aldehyde oxidase in HepG2 cells: Application to the investigation of enzyme inactivation. Drug Metabolism and Disposition. 2026;54(10):100397. doi:10.1016/j.dmd.2026.100397

BibTeX
@article{Ng2026,
  author = {Ng, Nicholas Kai Ming and Chan, Sian Wen and Lim, Andres Kai Zhi and Eng, Min Hao and Mettu, Vijaya Saradhi and Lau, Aik Jiang},
  title = {Idelalisib 8-oxidation as an enzyme-selective catalytic marker of human aldehyde oxidase in HepG2 cells: Application to the investigation of enzyme inactivation},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {10},
  pages = {100397},
  doi = {10.1016/j.dmd.2026.100397}
}
Kostenlos starten →